CYT 007 TNFQbAlternative Names: CYT007-TNFQb
Latest Information Update: 19 Sep 2008
At a glance
- Originator Cytos Biotechnology
- Class Antipsoriatics; Antirheumatics; Vaccines
- Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis